{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:43:15Z","timestamp":1788309795639,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016284","name":"Corporal Michael J Crescenz VA Medical Center Mental Illness Research Education and Clinical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016284","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidinnovations.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JID Innovations"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.xjidi.2024.100337","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:41:41Z","timestamp":1733791301000},"page":"100337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Development and Evaluation of the Dermatomyositis Outcomes for Muscle and Skin as an Outcome Measure in Dermatomyositis Clinical Trials"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9928-6018","authenticated-orcid":false,"given":"Rachita","family":"Pandya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8035-2953","authenticated-orcid":false,"given":"Joshua","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6232-7813","authenticated-orcid":false,"given":"Julianne","family":"Kleitsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2707-8134","authenticated-orcid":false,"given":"Darosa","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4679-665X","authenticated-orcid":false,"given":"Barbara","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3030-5369","authenticated-orcid":false,"given":"Victoria P.","family":"Werth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xjidi.2024.100337_bib1","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xjidi.2024.100337_bib2","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","volume":"76","author":"Aggarwal","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.xjidi.2024.100337_bib3","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.18223","article-title":"Evaluating important change in cutaneous disease activity as an efficacy measure for clinical trials in dermatomyositis","volume":"182","author":"Ahmed","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2024.100337_bib4","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.semarthrit.2020.01.002","article-title":"The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: a comprehensive review","volume":"50","author":"Ahmed","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.xjidi.2024.100337_bib5","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bjd.13915","article-title":"Validation of the cutaneous dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change","volume":"173","author":"Anyanwu","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2024.100337_bib6","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1002\/ski2.357","article-title":"Control of dermatomyositis skin disease activity lags behind control of muscles disease activity during the early treatment stages of classic dermatomyositis: a retrospective, single-centre study","volume":"4","author":"Bhatt","year":"2024","journal-title":"Skin Health Dis"},{"key":"10.1016\/j.xjidi.2024.100337_bib7","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xjidi.2024.100337_bib8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xjidi.2024.100337_bib9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00005792-197707000-00001","article-title":"Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis","volume":"56","author":"Bohan","year":"1977","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.xjidi.2024.100337_bib10","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/mus.24566","article-title":"An overview of polymyositis and dermatomyositis","volume":"51","author":"Findlay","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.xjidi.2024.100337_bib11","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.jaad.2019.01.028","article-title":"Examining cutaneous disease activity as an outcome measure for clinical trials in dermatomyositis","volume":"80","author":"Gaffney","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2024.100337_bib12","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jaad.2010.10.016","article-title":"Quality of life in dermatomyositis","volume":"65","author":"Goreshi","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2024.100337_bib13","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/jid.2011.440","article-title":"Evaluation of reliability, validity, and responsiveness of the CDASI and the CAT-BM","volume":"132","author":"Goreshi","year":"2012","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2024.100337_bib14","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/bjd.15006","article-title":"Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b2 in dermatomyositis","volume":"176","author":"Huard","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2024.100337_bib15","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2133.2008.08711.x","article-title":"Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis","volume":"159","author":"Klein","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2024.100337_bib16","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1007\/s00403-023-02625-2","article-title":"The physical and emotional impact of cutaneous dermatomyositis: a qualitative study","volume":"315","author":"Kleitsch","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.xjidi.2024.100337_bib17","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/bjd.15278","article-title":"Expanding the use of the Cutaneous Dermatomyositis Area and Severity Index (CDASI) to nondermatologists","volume":"176","author":"Kurtzman","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2024.100337_bib18","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups [published correction appears in Arthritis Rheumatol 2018;70:1532]","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.xjidi.2024.100337_bib19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fneur.2016.00064","article-title":"Idiopathic inflammatory myopathies: clinical approach and management","volume":"7","author":"Malik","year":"2016","journal-title":"Front Neurol"},{"key":"10.1016\/j.xjidi.2024.100337_bib20","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.jid.2023.05.025","article-title":"Validation of cutaneous dermatomyositis disease Area and severity index activity score and other efficacy outcomes as measures of skin disease in dermatomyositis in the lenabasum Phase 3 trial","volume":"143","author":"Pandya","year":"2023","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2024.100337_bib21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaad.2024.02.007","article-title":"Clinical characteristics and symptom progression of dermatomyositis subtypes: A retrospective analysis of a prospective database","volume":"91","author":"Pandya","year":"2024","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2024.100337_bib22","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1002\/acr.20532","volume":"63","author":"Rider","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.xjidi.2024.100337_bib23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/bjd.13167","article-title":"Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life","volume":"172","author":"Robinson","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.xjidi.2024.100337_bib24","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1016\/j.jid.2022.03.029","article-title":"Safety and efficacy of lenabasum, a cannabinoid receptor Type 2 agonist, in patients with dermatomyositis with refractory skin disease: a randomized clinical trial","volume":"142","author":"Werth","year":"2022","journal-title":"J\u00a0Invest Dermatol"}],"container-title":["JID Innovations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026724000857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026724000857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T08:01:12Z","timestamp":1741852872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667026724000857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2667026724000857"],"URL":"https:\/\/doi.org\/10.1016\/j.xjidi.2024.100337","relation":{},"ISSN":["2667-0267"],"issn-type":[{"value":"2667-0267","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and Evaluation of the Dermatomyositis Outcomes for Muscle and Skin as an Outcome Measure in Dermatomyositis Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"JID Innovations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xjidi.2024.100337","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}],"article-number":"100337"}}